anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Plasmodium vivax was thought not to be a problem in Duffy blood group negative Africans. However, recent research has found that P. vivax infection occurs not only in areas where Duffy-positive and -negative people live side-by-side, but also in areas where populations are predominantly Duffy-negative, such as Bandiagara, Mali. In this region, our research group recently observed 25 P. vivax infections in children, all of whom were Duffy-negative. Furthermore, some preliminary data suggest that, despite having extremely low parasitemia and no malarial symptoms (no fever, muscle aches, or chills), the children of Bandiagara with P. vivax may have a drop in hemoglobin.

The present study involves two substudies to detect P. vivax infections in children and adults of two predominantly Duffy-negative Malian populations where P. vivax infections have previously been identified. The cohort study will be conducted in the Bandiagara region. We will conduct physical exams and collect blood, urine, and stool samples at baseline and monthly (urine samples will be collected only at baseline) for about 10 months. Our goal is to detect and characterize P. vivax infections, focusing on molecularly characterizing how P. vivax invades erythrocytes in Duffy-negative individuals. Specifically, we want to identify the parasite ligands involved in this invasion. We will use RNA sequencing (RNAseq) of P. vivax in blood samples of infected subjects to define the level of expression of parasite invasion ligands. From the parasite DNA found in blood samples, we will determine whether there is gene expansion of the parasite ligand Duffy binding protein (PvDBP) (the number of copies of PvDBP in each genome), and identify the sequence of PvDBP to determine whether it can bind an erythrocyte receptor other than the Duffy blood group antigen (i.e., Duffy-negative erythrocytes). An additional focus will be whether P. vivax leads to anemia in the Duffy-negative children.

In addition, we will conduct a cross-sectional study to investigate the prevalence of P. vivax in the general population in Yirimadio, a periurban setting of Bamako, which is the sole place in Mali besides Bandiagara where P. vivax infections have been reported in Duffy-negative individuals. This will be achieved by undertaking a cross-sectional survey. Subjects will provide blood for blood smear and filter paper analyses to identify the presence of P. vivax infection at 3 different time points.
The safety and effectiveness of EVRYSDI in pediatric patients (neonates and older) have been established. Use of EVRYSDI for SMA is supported by evidence from adequate and well-controlled studies of EVRYSDI in patients 2 months of age and older with SMA. Use of EVRYSDI for SMA in patients 2 months of age and younger is supported by pharmacokinetic and safety data from pediatric patients 16 days and older, and pharmacokinetic modeling and simulation to identify the dosing regimen [see Clinical Pharmacology (12.3) and Clinical Studies (14)]. 

Juvenile Animal Toxicity Data

Oral administration of risdiplam (0, 0.75, 1.5, 2.5 mg/kg/day) to young rats from postnatal day (PND) 4 through PND 31 resulted in decreased growth (body weight, tibia length) and delayed sexual maturation in males at the mid and high dose. The skeletal and body weight deficits persisted after cessation of dosing. Ophthalmic changes consisting of vacuoles in the anterior vitreous were seen at the high dose. Decreases in absolute B lymphocyte counts were observed at all doses after cessation of dosing. Decreases in testis and epididymis weights, which correlated with degeneration of the seminiferous epithelium in the testis, occurred at the mid and high doses; the histopathology findings were reversible, but organ weight persisted after cessation of dosing. Impaired female reproductive performance (decreased mating index, fertility index, and conception rate) was observed at the high dose. A no-effect dose for adverse developmental effects on preweaning rats was not identified. The lowest dose tested (0.75 mg/kg/day) was associated with plasma exposures (AUC) lower than that in humans at the maximum recommended human dose (MRHD) of 5 mg/day.

Oral administration of risdiplam (0, 1, 3, or 7.5 mg/kg/day) to young rats from PND 22 through PND 112 produced a marked increase in micronuclei in the bone marrow, male reproductive organ histopathology (degeneration/necrosis of the seminiferous tubule epithelium, oligo/aspermia in the epididymis, spermatic granulomas), and adverse effects on sperm parameters (decreased sperm concentration and motility, increased sperm morphology abnormalities) at the highest dose tested. Increases in T lymphocytes (total, helper, and cytotoxic) were observed at the mid and high doses. The reproductive and immune effects persisted after cessation of dosing. The no-effect dose (1 mg/kg/day) for adverse effects on postweaning juvenile rats was associated with plasma exposures (AUC) lower than that in humans at the MRHD.
Chronic kidney disease (CKD) adversely affects the heart. The underlying mechanism and the interplay between the kidney and the heart are still obscure. We examined the cardiac effect using the unilateral ureteral obstruction (UUO)-induced CKD pre-clinical model in mice. Echocardiography, histopathology of the heart, myocardial mRNA expression of ANP and BNP, the extent of fibrotic (TGF-β, α-SMA, and collagen I) and epigenetic (histone deacetylases, namely HDAC3, HDAC4, and HDAC6) proteins, and myocardial inflammatory response were assessed. Six weeks of post-UUO surgery, we observed a compromised left-ventricular wall thickness and signs of cardiac hypertrophy, accumulation of fibrosis associated, and inflammatory proteins in the heart. In addition, we observed a perturbation of epigenetic proteins, especially HDAC3, HDAC4, and HDAC6, in the heart. Pharmacological inhibition of HDAC6 using ricolinostat (RIC) lessened cardiac damage and improved left-ventricular wall thickness. The RIC treatment substantially restored the serum cardiac injury markers, namely creatine kinase-MB and lactate dehydrogenase (LDH) activities, ANP and BNP mRNA expression, and heart histological changes. The extent of myocardial fibrotic proteins, phospho-NF-κB (p65), and pro-inflammatory cytokines (TNF-α, IL-18, and IL-1β) were significantly decreased in the RIC treatment group. Further findings revealed the CKD-induced infiltration of CD3, CD8a, CD11c, and F4/80 positive inflammatory cells in the heart. Treatment with RIC substantially reduced the myocardial infiltration of these inflammatory cells. From these findings, we believe that CKD-induced myocardial HDAC6 perturbation has a deteriorative effect on the heart, and inhibition of HDAC6 can be a promising approach to alleviate CKD-induced myocardial remodeling.
FIELD: cosmetology.SUBSTANCE: group of inventions relates to a method for processing colored hair, to compositions used in such methods, and to their applications. A method for preventing color loss in colored hair is proposed, including bringing hair into contact with a composition that includes from 1 to 30% by wt. of one or more surfactants and at least one hydroxy-substituted aldehyde selected from 2-hydroxydecanal, 2-hydroxydodecanal, 2-hydroxytetradecanal, 2-hydroxyhexanal, 2-hydroxyoctanal, 2-hydroxypropanal, 6-hydroxyhexanal, 3-hydroxypropanal, 4-hydroxybut-2-enal, 2-hydroxybutanal, 3-hydroxybutanal and 4-hydroxybutanal. A composition for hair care is proposed, including from 1 to 30% by wt. of one or more surfactants and at least one specified hydroxy-substituted aldehyde. A method for hair coloring and a packaged product for hair coloring using the specified composition in combination with a coloring composition are also proposed.EFFECT: inventions contribute to counteracting color loss of colored hair, provide a reduction in color loss by at least 10% after three washing sessions.26 cl, 1 dwg, 3 tbl, 4 ex
Endoscopic submucosa dissection (ESD) allows complete excision of the whole lesion, which results in a higher percentage of complete excision and an improved quality of life by minimizing the amount of excision as opposed to an endoscopic mucosal resection (EMR). Although ESD is now being carried out in the majority of hospitals, ESD's possible complications (such as trauma and perforation) have given rise to doubts about ESD practices in patients with early-stage stomach cancer when deciding on therapy and reimbursement. This study was designed to evaluate the effectiveness and safety of ESD over EMR in treating early-stage stomach cancer. Four main databases have been searched, including EMBASE and published. The ROBINS-I tool suggested in the Cochrane Handbook has been applied to evaluate the quality of the chosen trials. It may better reflect the risk of bias in the included studies. The meta-analyses were carried out with ReMan 5.3, and the results were treated with endote. Seven cohort studies have been completed. Meta analysis indicated that EMR and ESD surgery did not differ significantly from each other in terms of postoperative haemorrhage (OR, 0.76; 95%CI, 0.56,1.04 p = 0.09); EMR, however, was associated with a lower rate of postoperative perforation than ESD surgery (OR, 0.36; 95%CI, 0.24,0.54 p < 0.0001). Taking into account that ESD and EMR did not differ significantly in the risk of wound bleeding, even though the risk of perforation is not likely to result in life-threatening illness. In the analysis of these data, however, the potential advantages of EMR might be greater than ESD.
Among the symptoms presented by patients with SARS-Cov-2 infection, we can find various otorhinolaryngological alterations. Dysphonia appears in up to 79% of infected patients during the acute phase. Dysphonia can also occur as a sequelae, often underestimated, possibly due to its appearance along with other symptoms, also in patients after prolonged intubation or tracheostomy. We present a systematic review of the literature with a bibliographic search in PubMed, Cochrane and Google Scholar, with MESH terms including studies in English and Spanish. The results of the studies found and the vocal manifestations in patients during COVID-19 disease and the consequences produced are analysed. Dysphonia is an acute manifestation of COVID-19 with alterations in aerodynamic and acoustic analysis and in fibrolaryngoscopy. Post-COVID dysphonia can be a persistent symptom that is often underestimated, requiring multidisciplinary management and speech therapy intervention. Laryngeal sequelae are common in post-intubation or post-tracheostomy patients and are related to intubation time, tube number, pronation and respiratory sequelae.
PROBLEM TO BE SOLVED: To obtain the subject compound as E-form in high yield through few processes capable of producing cephalosporin derivatives having antibacterial action in an industrially advantageous way, by reaction of a specific compound with a disulfide compound in the presence of a phosphorus compound. SOLUTION: This compound of formula II (R<4> is a group interposed with a sulfur atom) is obtained by reaction of a compound of formula I (R<1> is a protected or acrylated amino; R<2> is carboxyl) or a salt thereof with a disulfide compound in the presence of a phosphorus compound (pref. a trivalent phosphorus compound such as tri-n-butylphosphine), wherein the disulfide compound is e.g. a compound of the formula r<5> -S-S-R<5> (R<5> is a hydrocarbon or heterocycle) such as 4-pyridyl sulfide. The amounts of the disulfide compound and the phosphorus compound to be used are pref. 1.5-2 equivalents and 1.1-1.2 equivalents per mol of the compound (salt) of formula I, respectively; and the above reaction is normally carried out in a solvent (pref. N-methylpyrrolidone).
Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
The invention relates to a method for making healthcare tonic wine. High-quality baijiu, especially old baijiu, is adopted as base liquor, only lycium barbarum, longan and tremella fuciformis are matched, and the finished product is obtained through refining processing. The baijiu accounts for 50 parts by weight, the lycium barbarum accounts for 2-3 parts by weight, the longan accounts for 3-5 parts by weight, and the tremella fuciformis accounts for 4-6 parts by mass. The old baijiu with the ethyl alcohol concentration being 32-55% is adopted as the baijiu. The healthcare tonic wine is suitable for being drunk by the old and the weak, and is also suitable for being drunk by young men, middle-aged people and postadolescent. The healthcare tonic wine contains multiple microelements and vitamins, and has the functions of tonifying the liver and kidneys, replenishing vital essence to improve eyesight, strengthening the spleen and stomach, clearing the intestines and nourishing yin and moisturizing the lung on the human body.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to novel benzoxazine and pyridooxazine compounds of the formula (1)   where a moiety Q means a condensed phenyl or condensed pyridyl; Z 1  means hydrogen, halogen atom, C 1 -C 6 -alkyl, phenyl, nitro-group, sulfonylamino-group or trifluoromethyl-group; Z 2  means hydrogen or halogen atom; X means hydrogen or oxygen atom; A means C 1 -C 6 -alkyl, C 1 -C 6 -alkylaryl or C 1 -C 6 - alkylheterocyclyl where aryl and heterocyclyl are described in the invention claim; n is a whole number from 0 to 3; Y means a moiety described in the invention claim, and to their pharmaceutically acceptable salts, esters and promedicinal forms. Invention discloses also methods of their synthesis, intermediate compounds, pharmaceutical compositions based on thereof showing an antibacterial activity and to methods of treatment of bacterial infections. Invention can be used in medicine as anti-infectious agents. EFFECT: new compounds indicated above, improved methods of synthesis and treatment, valuable medicinal property. 32 cl, 2 tbl
Participants in this arm will receive a sham filter for their box fans. These filters receive a MERV rating of 1 and only filter very large particles and debris such as lint, hair and insects. These particles have little to no impact on asthma symptoms. MERV stands for "minimum efficiency reporting value" and a filter receives a MERV rating as determined by the American Society of Heating, Refrigeration, and Air-Conditioning Engineers.
Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
The safety, efficacy, and pharmacokinetics of IXINITY have been evaluated in previously treated pediatric patients (PTP). Subjects received twice or once weekly prophylaxis treatment (four subjects were prescribed once a week treatment, 17 were prescribed twice a week treatment) with IXINITY for a mean of 158.7 exposure days [see Clinical Studies (14)].

Compared to adolescents and adults (≥ 12 years old), children (< 12 years old) showed higher Factor IX body weight-adjusted clearance, shorter half-life, and lower recovery. Adjustment in dose or dosing frequency may be needed [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)].

There were no inhibitors detected [see Clinical Pharmacology (12.6)]. One patient in the pediatric study had an adverse reaction of hypersensitivity resulting in withdrawal from the study. No new safety concerns were identified in the pediatric trial [see Adverse Reactions (6.1)].
Mapping between data defining a plurality of automated interventions and a patient state defined with respect to multiple patient parameters following forming a set of requests to a patient and receiving patient responses and providing the selected intervention to the patient. Interventions may relate to musculoskeletal or physiotherapy content which may be pre-recorded, cgi or live video content from a human presenter. This allows physical exercises to be provided that are suitable for the patient, and feedback to be obtained, for example over internet for streamed content. A GAN-based neural network may be used to provide generative or pre-defined individualised content suited to a user, pursuing quality of life elements through attending treatment. Streaks, leaderboards and social accountability may be used to ensure patient remains motivated and engaged. Data may be collected from response buttons on user device, a wearable device or camera imaging.
RATIONALE: Current guidelines define a severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as an increase in symptoms requiring hospital admission or emergency department (ED) visit. Little is known about whether or not subjects requiring hospitalization and those needing only ED care have similar patient profiles and if their clinical outcomes appear comparable.
OBJECTIVE: The main goals of this study were to compare the demographic and clinical characteristics of patients treated for an AECOPD with an inpatient admission versus an ED visit and to review if hospital resource utilization was different between the 2 groups after discharge.
METHODS: Subjects treated in 2022 at Montfort Hospital for an AECOPD were reviewed. Patient demographic information was collected in addition to spirometry results and blood eosinophil counts on file. Supplemental oxygen use and medication lists were also recorded. Patients with an initial hospital admission were compared to those requiring only ED care with univariate and multivariate analyses. We also assessed if subjects were again treated for an AECOPD up to 6 months post initial discharge, and if so, the type of hospital visits (hospitalization or ED).
MEASUREMENTS AND MAIN RESULTS: A total of 135 individuals necessitated hospitalization and 79 received ED care for the treatment of an AECOPD. On univariate analysis, patients requiring an inpatient stay appeared older and were more likely to have spirometry results on file. A greater proportion of hospitalized individuals were on supplemental oxygen and prescribed at least one long-acting inhaled medication. These studied variables remained significant after multivariate logistic regression analysis. Subjects with an initial inpatient admission were also more likely to require hospitalization upon repeat presentation for a severe AECOPD.
CONCLUSION: Given the important differences observed in both patient characteristics and hospital resource utilization, this study supports considering an AECOPD requiring inpatient admission versus an ED visit as distinct categories of events.
<P>PROBLEM TO BE SOLVED: To provide a medicament for treating complication of true diabetes mellitus.  <P>SOLUTION: This drug was prepared by fermentation of licorice followed by getting a lot of glycerizine using hydrochloric acid and not by boiling for fear of destruction of enzymes and flavonoids. The licorice prepared by fermentation is rich in amylase which improves diabetic complications due to increase of cellular enzymatic activity. Many diabetic complications such as nephropathy, peripheral neuritis, cataract and retinopathy have shown improvement with flavonoids present in licorice. It has been found that this effect is caused from the prevention of transformation of glucose to sorbitol by inhibiting aldose reductase enzyme, thus avoiding the accumulation of sorbitol in several tissues including lens, retina, kidney, blood vessels, peripheral nerves and striated muscles.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The study will be a Randomized clinical trial and will be conducted in services hospital lahore. The study will be completed within the duration of ten months. Non probability convenient sampling study technique will be used to collect the data. The sample size of 50 patients will be taken in this study to find the effects of high intensity interval training versus moderate intensity exercises on physical health and cardiorespiratory fitness in obese women.

Patients will be divided into two groups (Group A will be treated with high intensity interval training and Group B will be treated with moderate intensity exercises). Eligible participants attended three session per week. Overnight fast, resting metabolic rate and blood pressure will be assessed. An oral glucose test will be assessed and baseline blood samples will be used for lipoprotein analysis. Pacer test and step test performed in the each session. A regular follow-up visits to department and a final assessment will be made at the end of last week by using questionnaire and resulting improvement will shown in results after completion. Data will be analyzed on SPSS 25.
The invention discloses water-soluble low-molecular-weight polysaccharide with anti-tumor activity for artificially cultured cordyceps mycelium, a preparation method and an application thereof. 30 percent ethanol is used as extractant, and the best extraction process of the polysaccharide has the temperature of 70 DEG C, material-liquid ratio of 1 to 20, and extracting time of 2 hours. The polysaccharide is subjected to grease removal, protein removal, 50 percent ethanol precipitation and 70 percent ethanol precipitation to prepare crude polysaccharide after freezing and drying. The crude polysaccharide is purified grade by grade through a DEAE Sephadex A-25 column and a Sephadex G-75 column to prepare the water-soluble low-molecular-weight polysaccharide. The polysaccharide has higher purity, wherein the polysaccharide content is 94.57 percent, and relative molecular mass is about 9,874. The water-soluble polysaccharide has obvious inhibiting effect on proliferation of liver cancer cell line Bel-7204 and gastric cancer cell line SGC-7901 of human beings, and has obvious inhibiting effect on growth of S180 tumor cells implanted in a mouse body. The water-soluble low-molecular-weight cordyceps polysaccharide has clear active components and controllable quality, and can be used as an anti-tumor medicament or a health-care product for improving body immunity.
The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
The effect of intraoperative anesthesia depth monitoring on delirium occurrence and improvement of nursing quality in the post-anesthesia care unit (PACU) remains unclear. We aimed to explore the effect of intraoperative anesthesia bispectral index (BIS) monitoring on delirium occurrence and improvement of nursing quality in the PACU for patients recovering from general anesthesia.

This randomized controlled trial included 120 patients, aged 20-80 years and classified as grades I-III according to the American Society of Anesthesiologists. The BIS-guided group (group B) underwent intraoperative monitoring of BIS anesthesia depth (maintained within the anesthetic range \[40-60\]). The depth of anesthesia was not monitored in the non-BIS-guided group (group C). The patients' vital signs were recorded at the beginning of the operation (T0), upon entering the PACU (T1), 15 min after extubation (T2), and after leaving the PACU (T3). Delirium score, emergence period (extubation and PACU observation times), and adverse events in the PACU were monitored. The nursing activity score (NAS) was used to evaluate the quality of care.